Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells.
colorectal cancer
cyclooxygenase-2
epithelial-mesenchymal transition
platelet-derived extracellular vesicles
thromboxane A2
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 Jan 2023
05 Jan 2023
Historique:
received:
12
12
2022
revised:
30
12
2022
accepted:
01
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Platelet-cancer cell interactions modulate tumor metastasis and thrombosis in cancer. Platelet-derived extracellular vesicles (EVs) can contribute to these outcomes. We characterized the medium-sized EVs (mEVs) released by thrombin-stimulated platelets of colorectal cancer (CRC) patients and healthy subjects (HS) on the capacity to induce epithelial-mesenchymal transition (EMT)-related genes and cyclooxygenase (COX)-2( The mEV population released from thrombin-activated platelets of CRC patients had a different size distribution vs. HS. Platelet-derived mEVs from CRC patients, but not from HS, upregulated EMT marker genes, such as We show that mEVs released from thrombin-activated platelets of CRC patients have distinct features (size distribution and proteomics cargo) vs. HS and promote prometastatic and prothrombotic phenotypes in cancer cells. The analysis of platelet-derived mEVs from CRC patients could provide valuable information for developing an appropriate treatment plan.
Sections du résumé
BACKGROUND
BACKGROUND
Platelet-cancer cell interactions modulate tumor metastasis and thrombosis in cancer. Platelet-derived extracellular vesicles (EVs) can contribute to these outcomes.
METHODS
METHODS
We characterized the medium-sized EVs (mEVs) released by thrombin-stimulated platelets of colorectal cancer (CRC) patients and healthy subjects (HS) on the capacity to induce epithelial-mesenchymal transition (EMT)-related genes and cyclooxygenase (COX)-2(
RESULTS
RESULTS
The mEV population released from thrombin-activated platelets of CRC patients had a different size distribution vs. HS. Platelet-derived mEVs from CRC patients, but not from HS, upregulated EMT marker genes, such as
CONCLUSIONS
CONCLUSIONS
We show that mEVs released from thrombin-activated platelets of CRC patients have distinct features (size distribution and proteomics cargo) vs. HS and promote prometastatic and prothrombotic phenotypes in cancer cells. The analysis of platelet-derived mEVs from CRC patients could provide valuable information for developing an appropriate treatment plan.
Identifiants
pubmed: 36672299
pii: cancers15020350
doi: 10.3390/cancers15020350
pmc: PMC9856452
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : IG 2017- ID. 20365
Organisme : Aspirin for Cancer Prevention Group
ID : N/A
Organisme : the European Union - European Social Fund
ID : PON Research and Innovation 2014-2020 to Annalisa Contursi
Références
Hypertension. 2004 Feb;43(2):428-33
pubmed: 14718367
Micron. 2022 Oct;161:103341
pubmed: 35985059
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Thromb Haemost. 2007 Jan;97(1):119-23
pubmed: 17200778
Mol Pharmacol. 2013 Jul;84(1):25-40
pubmed: 23580446
Thromb Haemost. 2009 Oct;102(4):711-8
pubmed: 19806257
J Clin Invest. 1997 May 1;99(9):2118-27
pubmed: 9151784
J Thromb Haemost. 2018 Jun;16(6):1236-1245
pubmed: 29575716
Int J Mol Sci. 2020 Oct 15;21(20):
pubmed: 33076339
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
J Lipid Res. 2021;62:100109
pubmed: 34428433
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374539
J Am Coll Cardiol. 2016 Aug 30;68(9):967-76
pubmed: 27561771
Cancer Res. 2018 Jul 1;78(13):3407-3412
pubmed: 29921699
Oncotarget. 2017 Oct 27;8(57):97464-97475
pubmed: 29228624
Oncol Lett. 2012 Feb;3(2):441-444
pubmed: 22740928
Curr Protoc Cytom. 2018 Oct;86(1):e43
pubmed: 30168659
J Thromb Haemost. 2014 Aug;12(8):1320-30
pubmed: 24942808
Cancer Biomark. 2018;21(4):805-812
pubmed: 29400660
Oncogene. 2010 Feb 11;29(6):781-8
pubmed: 19946329
Int J Cancer. 2016 Feb 15;138(4):939-48
pubmed: 26341361
Semin Oncol. 2014 Jun;41(3):346-58
pubmed: 25023350
Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19204-9
pubmed: 22080605
Int J Cancer. 2005 Feb 20;113(5):752-60
pubmed: 15499615
Tumour Biol. 2016 Jan;37(1):185-97
pubmed: 26602382
Oncotarget. 2015 Jun 30;6(18):15966-83
pubmed: 25965826
Blood Adv. 2022 Jan 11;6(1):307-320
pubmed: 34649273
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
BMC Cancer. 2011 Feb 01;11:49
pubmed: 21284870
Front Pharmacol. 2019 Jan 22;10:7
pubmed: 30723407
Proteomics. 2018 Aug;18(15):e1800219
pubmed: 29932309
J Thromb Haemost. 2019 Sep;17(9):1511-1521
pubmed: 31207003
Cancer Metastasis Rev. 2018 Sep;37(2-3):455-467
pubmed: 29855749
Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):15-26
pubmed: 21160064
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
Anticancer Res. 2005 Jan-Feb;25(1A):225-33
pubmed: 15816542
Contemp Oncol (Pozn). 2013;17(4):389-93
pubmed: 24592128
Curr Opin Hematol. 2010 Nov;17(6):578-84
pubmed: 20739880
J Biol Chem. 1999 Mar 12;274(11):7545-56
pubmed: 10066822
Blood. 2009 Jan 29;113(5):1112-21
pubmed: 18802008
J Clin Invest. 2001 Jul;108(1):7-13
pubmed: 11435450
Oncotarget. 2017 Jun 6;8(44):75952-75967
pubmed: 29100283
Adv Sci (Weinh). 2020 May 26;7(13):2000112
pubmed: 32670759
Biomed Res Int. 2014;2014:102478
pubmed: 24783193
Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10330-4
pubmed: 9294210
Blood. 2009 Mar 19;113(12):2835-42
pubmed: 19036702
Cancer Res. 1985 Aug;45(8):3790-5
pubmed: 4016751
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19836-41
pubmed: 19901330
Int J Mol Sci. 2013 Oct 16;14(10):20768-92
pubmed: 24135872
Nat Rev Cancer. 2010 Mar;10(3):181-93
pubmed: 20168319
TH Open. 2017 Dec 15;1(2):e155-e163
pubmed: 31249921
Biochem Soc Trans. 2015 Aug;43(4):707-14
pubmed: 26551717
J Thromb Haemost. 2020 Apr;18(4):771-780
pubmed: 31898400
Oncotarget. 2016 May 31;7(22):32462-77
pubmed: 27074574
PLoS One. 2013;8(4):e60299
pubmed: 23560089
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
J Am Coll Cardiol. 2008 Aug 26;52(9):743-9
pubmed: 18718422
Adv Exp Med Biol. 1999;447:181-91
pubmed: 10086194
Int J Mol Sci. 2020 Oct 23;21(21):
pubmed: 33114229
Vascul Pharmacol. 2017 Feb;89:1-11
pubmed: 28089842
Front Pharmacol. 2019 Nov 08;10:1256
pubmed: 31780927
J Clin Invest. 2011 Nov;121(11):4462-76
pubmed: 22005299
Pharmacol Ther. 2008 Apr;118(1):18-35
pubmed: 18374420